Effect of Ayurveda intervention AYUSH-64 add-on therapy for patients with COVID-19 infection (Stage I)

Evaluation of Efficacy and Safety of Ayurveda Intervention (Ayush-64) add-on therapy for patients with COVID-19 infection (Stage I)-A Randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/05/025156

Enrollment

Registered

2020-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Group I: Ayurveda intervention AYUSH-64 as add-on to standard treament: AYUSH 64: 2 Tablets (500mg each) thrice daily with water after meal for 1 month Control Intervention1: Group II:

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of 18-60 yrs of age, clinically diagnosed with corona virus disease 2019 by RTPCR test coming under stage I- mild (Early infection)- Group A, B, C as per TREATMENT PROTOCOL FOR CONFIRMED COVID-19 PATIENTS (Maharashtra Health Services_15 April 2020.) 2.Participants who can take medicines orally. 3.Patients willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Pregnant, Lactating women, patients with CKD (Chronic Kidney Disease). 2.Not willing to participate in the study.

Design outcomes

Primary

Measure	Time frame
1.Clinical cure rate: Time to negative conversion of severe acute respiratory syndrome corona-virus 2.Timepoint: At baseline, 4 weeks	—

Secondary

Measure	Time frame
1.Duration of fever and each of the respiratory symptoms. 2.Improvement in hematological and laboratory parameters (CBC, LFT, RFT, RBS, ESR, Hs-CRP, LDH, CXR, ABG, S. Ferritin, D-dimer, ECG). 3.No of cases Reporting any ADR/AE. 4.Number of patients referred. 5.Number of cases that required invasive or non-invasive oxygen therapy during the intervention. 6.Number of cases that progressed to multi-organ failure while under clinical trial.Timepoint: 1 Month	—

Measure

Time frame

1.Duration of fever and each of the respiratory symptoms. 2.Improvement in hematological and laboratory parameters (CBC, LFT, RFT, RBS, ESR, Hs-CRP, LDH, CXR, ABG, S. Ferritin, D-dimer, ECG). 3.No of cases Reporting any ADR/AE. 4.Number of patients referred. 5.Number of cases that required invasive or non-invasive oxygen therapy during the intervention. 6.Number of cases that progressed to multi-organ failure while under clinical trial.Timepoint: 1 Month

—

Countries

India

Contacts

Public ContactDr R Govind Reddy

Regional Ayurveda Research Institute for Mother and Child Health, Nagpur

drrgreddy68@gmail.com9820284671

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026